Postoperative chemotherapy significantly improves survival of elderly patients with stage IB‐II non‐small cell lung cancer: A population‐based study

Wujianhong Liu,Shangshang Ma,Pingfan Shi,Yanfei Zhang,Ming Li
DOI: https://doi.org/10.1002/cam4.5834
IF: 4.711
2023-04-11
Cancer Medicine
Abstract:For patients aged ≥70 years, postoperative chemotherapy can improve the survival rate for those with stage IB and II, and decrease the survival rate for stage IA patients. Therefore, when using chemotherapy, it is necessary to prioritizing the patient's staging along with other vital factors such as age, grade, and other variables in formulating a successful treatment scheme. Background There is scant evidence‐based information about survival benefits of postoperative chemotherapy in elderly patients with early‐stage non‐small cell lung cancer (NSCLC). The purpose of this study is to compare the overall survival (OS) and cancer‐specific survival (CSS) rates of surgery alone versus postoperative chemotherapy in patients aged ≥70 years with stage I‐II NSCLC. Methods Elderly patients aged ≥70 years diagnosed with stage I‐II NSCLC were selected from the Surveillance, Epidemiology, and End Results (SEER) database from January 1, 2010 to December 31, 2015. OS and CSS were compared between the two groups utilizing overlap weighting analysis, inverse probability of treatment weight (IPTW), and propensity score matching (PSM). Results Of the 7193 included patients with stage I‐II NSCLC who are more than 70 years old, 681 patients (9.5%) received postoperative chemotherapy and 6512 patients (90.5%) received surgery‐alone. Median OS was 77 months in postoperative chemotherapy group versus 79 months in surgery‐alone group (p = 0.89). The result of IPTW analysis showed the similar results. The probability of patients choosing chemotherapy increased with the AJCC stage and Grade increasing (p
oncology
What problem does this paper attempt to address?